Comparison Between Low-Dose Chemotherapy and Surgery for the Treatment of Extremity-Associated Solitary Bone Lesions in Children With Langerhans Cell Histiocytosis in South China: A Case-Control Study

    February 2018 in “ Journal of bone oncology ”
    Hongyi Li, Xianbiao Xie, Junqiang Yin, Jian Tu, Xiaoshuai Wang, Weihai Liu, Jiajun Zhang, Hongbo Li, Changye Zou, Yongqian Wang, Jingnan Shen, Gang Huang
    TLDR Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.
    This study compared low-dose chemotherapy (LDC) and surgery for treating solitary bone lesions of Langerhans cell histiocytosis in children, involving 87 patients. LDC led to shorter hospital stays, faster symptom relief, and quicker recovery times compared to surgery, with mild chemotherapy-related side effects. Surgery patients experienced complications like pathologic fractures and infections. LDC resulted in longer relapse-free survival (87 months vs. 59 months for surgery) and better health-related quality of life at 3 months post-treatment. Additionally, LDC was more cost-effective. Overall, LDC was considered a safer, less invasive, and more effective treatment option for pediatric SBL-LCH in the extremities.
    Discuss this study in the Community →